Raphas Co. Ltd (214260) - Net Assets

Latest as of September 2025: ₩32.62 Billion KRW ≈ $22.10 Million USD

Based on the latest financial reports, Raphas Co. Ltd (214260) has net assets worth ₩32.62 Billion KRW (≈ $22.10 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩82.76 Billion ≈ $56.08 Million USD) and total liabilities (₩50.14 Billion ≈ $33.98 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Raphas Co. Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩32.62 Billion
% of Total Assets 39.41%
Annual Growth Rate 3.08%
5-Year Change -33.54%
10-Year Change N/A
Growth Volatility 52.95

Raphas Co. Ltd - Net Assets Trend (2017–2024)

This chart illustrates how Raphas Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Raphas Co. Ltd balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for Raphas Co. Ltd (2017–2024)

The table below shows the annual net assets of Raphas Co. Ltd from 2017 to 2024. For live valuation and market cap data, see how much is Raphas Co. Ltd worth.

Year Net Assets Change
2024-12-31 ₩29.36 Billion
≈ $19.90 Million
-9.12%
2023-12-31 ₩32.31 Billion
≈ $21.89 Million
-21.06%
2022-12-31 ₩40.93 Billion
≈ $27.74 Million
-21.83%
2021-12-31 ₩52.36 Billion
≈ $35.48 Million
+18.51%
2020-12-31 ₩44.18 Billion
≈ $29.94 Million
-7.63%
2019-12-31 ₩47.83 Billion
≈ $32.42 Million
+137.59%
2018-12-31 ₩20.13 Billion
≈ $13.64 Million
-15.21%
2017-12-31 ₩23.74 Billion
≈ $16.09 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Raphas Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 32695627000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock ₩4.46 Billion 15.19%
Other Components ₩25.68 Billion 87.46%
Total Equity ₩29.36 Billion 100.00%

Raphas Co. Ltd Competitors by Market Cap

The table below lists competitors of Raphas Co. Ltd ranked by their market capitalization.

Company Market Cap
Evrofarma SA
AT:EVROF
$54.15 Million
Speciality Restaurants Limited
NSE:SPECIALITY
$54.15 Million
Leader Electronics Inc
TW:3058
$54.16 Million
Rushil Decor Limited
NSE:RUSHIL
$54.17 Million
Archer Materials Ltd
AU:AXE
$54.10 Million
Changhae Ethanol Co. Ltd
KQ:004650
$54.09 Million
PS International Group Ltd. Ordinary Shares
NASDAQ:PSIG
$54.07 Million
Purple Innovation Inc
NASDAQ:PRPL
$54.06 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Raphas Co. Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 29,541,467,620 to 29,362,408,780, a change of -179,058,840 (-0.6%).
  • Net loss of 4,771,518,570 reduced equity.
  • Share repurchases of 2,707,221,670 reduced equity.
  • New share issuances of 293,400,000 increased equity.
  • Other factors increased equity by 7,006,281,400.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩-4.77 Billion -16.25%
Share Repurchases ₩2.71 Billion -9.22%
Share Issuances ₩293.40 Million +1.0%
Other Changes ₩7.01 Billion +23.86%
Total Change ₩- -0.61%

Book Value vs Market Value Analysis

This analysis compares Raphas Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.72x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 ₩3523.07 ₩9500.00 x
2018-12-31 ₩2987.35 ₩9500.00 x
2019-12-31 ₩5733.04 ₩9500.00 x
2020-12-31 ₩5248.46 ₩9500.00 x
2021-12-31 ₩6092.15 ₩9500.00 x
2022-12-31 ₩4839.82 ₩9500.00 x
2023-12-31 ₩3445.48 ₩9500.00 x
2024-12-31 ₩3492.01 ₩9500.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Raphas Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -16.25%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -17.53%
  • • Asset Turnover: 0.36x
  • • Equity Multiplier: 2.59x
  • Recent ROE (-16.25%) is below the historical average (-13.66%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2017 -22.76% -77.90% 0.20x 1.47x ₩-7.78 Billion
2018 -19.09% -38.23% 0.29x 1.71x ₩-5.86 Billion
2019 0.26% 0.69% 0.29x 1.31x ₩-4.66 Billion
2020 -10.28% -25.42% 0.30x 1.35x ₩-8.96 Billion
2021 9.42% 24.24% 0.21x 1.87x ₩-305.77 Million
2022 -20.79% -36.00% 0.25x 2.35x ₩-12.60 Billion
2023 -29.80% -31.52% 0.28x 3.40x ₩-11.76 Billion
2024 -16.25% -17.53% 0.36x 2.59x ₩-7.71 Billion

Industry Comparison

This section compares Raphas Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $368,573,438,392
  • Average return on equity (ROE) among peers: 0.96%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Raphas Co. Ltd (214260) ₩32.62 Billion -22.76% 1.54x $54.13 Million
ORIENTBIO Inc. (002630) $57.60 Billion 0.00% 0.70x $43.15 Million
Green Cross (005250) $1.51 Trillion 0.20% 0.84x $425.10 Million
Green Cross Holdings Preference Shares (005257) $1.85 Trillion 1.30% 0.98x $3.74 Million
Pharmicell (005690) $51.52 Billion 8.44% 0.23x $736.42 Million
GeneOne Life Science Inc (011000) $39.74 Billion 0.00% 0.49x $49.94 Million
HLB Co. Ltd (028300) $19.44 Billion 0.00% 0.66x $5.41 Billion
Daesung Microbiological Labs. Co. Ltd (036480) $37.00 Billion 2.34% 0.69x $19.29 Million
Seoulin Bioscience Co.Ltd (038070) $51.49 Billion 4.00% 0.38x $37.92 Million
Hyundai Bioscience Co. Ltd (048410) $58.24 Billion 3.27% 0.77x $872.13 Million
iNtRON Biotechnology Inc (048530) $11.93 Billion -9.93% 0.65x $77.34 Million

About Raphas Co. Ltd

KQ:214260 Korea Biotechnology
Market Cap
$54.13 Million
₩79.88 Billion KRW
Market Cap Rank
#21593 Global
#1397 in Korea
Share Price
₩9500.00
Change (1 day)
-1.96%
52-Week Range
₩9320.00 - ₩21150.00
All Time High
₩75400.00
About

Raphas Co., Ltd. manufactures and sells biodegradable microneedles in Korea. The company offers skin care, medical device, whitening care, and wrinkle care under the Acropass brand; and health food product under the FitKong brand. It also supplies double-layer microneedle manufacturing technology; and provides original development manufacturing, and contract development and manufacturing organiza… Read more